 In June 2016, ALK and Merck & Co announced that the partnership would end by the end of 2016.The company also has an alliance with Torii Pharmaceutical Co. Ltd to develop and commercialize ALK’s house dust mite allergy immunotherapy products in Japan.The agreement covers the house dust mite SLIT-tablet, an injection-based immunotherapy product, and diagnostic products for house dust mite allergy.